Lanz J, Reardon MJ, Pilgrim T, et al. - Regardless of treatment modality (TAVR: transcatheter aortic valve replacement with a supra‐annular, self‐expanding device, or SAVR: surgical aortic valve replacement), findings revealed a low cumulative risk of infective endocarditis (IE) among patients undergoing aortic valve replacement, although the TAVR implant group was found to have a lower risk of IE. High mortality was observed in the presence of IE.

• Pooling of data from 3 randomized clinical trials comparing TAVR to SAVR and from a prospective continued TAVR access study was done.

• IE occurred in 12 (0.5%) of 2249 patients receiving TAVR and 21 (1.1%) of 1828 patients undergoing SAVR.

• At 5 years, the cumulative incidence of IE was 1.01% post-TAVR and 1.58% post-SAVR.

• In IE cases, the rate of all‐cause mortality was 27.3% and 51.8% in TAVR and SAVR groups, respectively, at 1 year.